All In Biotech

NDA 220605 · Takeda Pharms Am

Mimrylo

Rusfertide Acetate · Subcutaneous

NovelPriority reviewOrphan

CDER novel approval, Aug 28, 2026: To treat erythrocytosis in adults with polycythemia vera

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Aug 28, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

6

2 Phase 3, 1 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 7, 2026.

MIMRYLO is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV). MIMRYLO is a hepcidin mimetic indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV). ( 1 )

Mechanism: Rusfertide is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin. Inhibition of ferroportin by rusfertide reduces availability of iron for production of red blood cells resulting in lower hematocrit levels.

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 28, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
5 products under this application
  • MIMRYLO · RUSFERTIDE ACETATE EQ 54MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
  • MIMRYLO · RUSFERTIDE ACETATE EQ 28MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
  • MIMRYLO · RUSFERTIDE ACETATE EQ 9.5MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
  • MIMRYLO · RUSFERTIDE ACETATE EQ 41MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
  • MIMRYLO · RUSFERTIDE ACETATE EQ 19MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rusfertide" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.